Page 1 | Search Results | The Hematologist | American Society of Hematology

Skip Nav Destination

1-20 of 26

Sort by

Sort Order Select

Articles

ASH Standing Committee Update

Michael Linenberger, MD, FACP, Sherif M. Badawy, MD, Joseph Mikhael, MD, MEd, FRCPC, FACP

The Hematologist (2016) 13 (5)

https://doi.org/10.1182/hem.V13.5.6550

Published: 2016

Articles

A Step Forward in Understanding Leukemogenesis in NPM1c+ AML

Michael Linenberger, MD, Fabiana Ostronoff, MD

The Hematologist (2011) 8 (6)

https://doi.org/10.1182/hem.V8.6.1214

Published: 2011

Articles

Into Thin Air: New Insights Into the Role of Hypoxia-Inducible Factor in Cancer and Ischemic Diseases

Michael Linenberger, MD, Heather Cheng, MD, PhD

The Hematologist (2011) 8 (5)

https://doi.org/10.1182/hem.V8.5.1234

Published: 2011

Articles

Personalized Antiplatelet Therapy for ACS Patients Treated With PCI - Are We There Yet?

Swaminathan Murugappan, MD, PhD, Michael Linenberger, MD

The Hematologist (2011) 8 (4)

https://doi.org/10.1182/hem.V8.4.1251

Published: 2011

Articles

Heparin: Everything Old is New Again

Michael Linenberger, MD, Junfeng Wang, MD, PhD

The Hematologist (2011) 8 (3)

Published: 2011

Articles

Polycythemia Vera

Bart Scott, MD, Michael Linenberger, MD

The Hematologist (2011) 8 (2)

https://doi.org/10.1182/hem.V8.2.6303

Published: 2011

Articles

Lost in Translation: Pulling the Switch on p53 Production in Dyskeratosis Congenita

Nicholas Burwick, MD, Michael Linenberger, MD

The Hematologist (2011) 8 (1)

https://doi.org/10.1182/hem.V8.1.6314

Published: 2011

Articles

Teasing Out Prognostic Markers in Hodgkin Lymphoma

Steven Rosinski, MD, PhD, Michael Linenberger, MD

The Hematologist (2010) 7 (6)

https://doi.org/10.1182/hem.V7.6.6277

Published: 2010

Articles

Optimizing the Dose for Prophylactic Platelet Transfusions: Will PLADO Shape the Future of Transfusion Practice?

Jaideep Shenoi, MD, Michael Linenberger, MD

The Hematologist (2010) 7 (5)

https://doi.org/10.1182/hem.V7.5.6264

Published: 2010

Articles

Iron Biovailability and Effective Erythropoiesis in β-Thalassemia: A Delicate Balancing Act

Soumit Basu, MD, PhD, Michael Linenberger, MD

The Hematologist (2010) 7 (3)

https://doi.org/10.1182/hem.V7.3.6256

Published: 2010

Articles

Double-Teaming EZH2 in AML

Brady Miller, MD, Michael Linenberger, MD

The Hematologist (2010) 7 (2)

https://doi.org/10.1182/hem.V7.2.6249

Published: 2010

Articles

mTOR: A Target for Enhancing Memory T-Cell Generation

Michael Linenberger, MD, Diane Krause, MD, PhD

The Hematologist (2010) 7 (1)

https://doi.org/10.1182/hem.V7.1.6260

Published: 2010

Articles

NETting the Enemy May Cause Collateral Damage to Self

William Hobbs, MD, PhD, Michael Linenberger, MD

The Hematologist (2009) 6 (6)

https://doi.org/10.1182/hem.V6.6.6185

Published: 2009

Articles

The Emerging Role of Prostaglandin E2 in Regulating Stem Cell Function

John Byon, MD, PhD, Michael Linenberger, MD

The Hematologist (2009) 6 (4)

https://doi.org/10.1182/hem.V6.4.6198

Published: 2009

Articles

There Goes the Neighborhood: The Leukemic Microenvironment Co-Opts Normal Hematopoietic Progenitor Cells From Their Supportive Marrow Niche

Michael Linenberger, MD

The Hematologist (2009) 6 (2)

https://doi.org/10.1182/hem.V6.2.6204

Published: 2009

Articles

Down-Regulation of PML: A Wake-Up Call for Leukemia-Initiating Cells

Michael Linenberger, MD

The Hematologist (2009) 6 (1)

https://doi.org/10.1182/hem.V6.1.6166

Published: 2009

Articles

Increased Risk of VTE Associated With Impaired Clot Lysis: A New Dimension to Virchow's Triad

Michael Linenberger, MD

The Hematologist (2008) 5 (5)

https://doi.org/10.1182/hem.V5.5.6118

Published: 2008

Articles

Optimism and Caution on the Use of MSCs in Patients Undergoing HSCT for Hematologic Malignancies

Michael Linenberger, MD

The Hematologist (2008) 5 (4)

https://doi.org/10.1182/hem.V5.4.6126

Published: 2008

Articles

Clinical Penetrance of HFE Hereditary Hemochromatosis, Serum Ferritin Levels, and Screening Implications: Can We Iron This Out?

Michael Linenberger, MD

The Hematologist (2008) 5 (3)

https://doi.org/10.1182/hem.V5.3.6103

Published: 2008

Articles

A Bank Without Assets: Ex Vivo Storage Depletes RBC NO Bioactivity

Michael Linenberger, MD

The Hematologist (2008) 5 (1)

https://doi.org/10.1182/hem.V5.1.6094

Published: 2008

NARROW

ASH Standing Committee Update

A Step Forward in Understanding Leukemogenesis in NPM1c+ AML

Into Thin Air: New Insights Into the Role of Hypoxia-Inducible Factor in Cancer and Ischemic Diseases

Personalized Antiplatelet Therapy for ACS Patients Treated With PCI - Are We There Yet?

Heparin: Everything Old is New Again

Polycythemia Vera

Lost in Translation: Pulling the Switch on p53 Production in Dyskeratosis Congenita

Teasing Out Prognostic Markers in Hodgkin Lymphoma

Optimizing the Dose for Prophylactic Platelet Transfusions: Will PLADO Shape the Future of Transfusion Practice?

Iron Biovailability and Effective Erythropoiesis in β-Thalassemia: A Delicate Balancing Act

Double-Teaming EZH2 in AML

mTOR: A Target for Enhancing Memory T-Cell Generation

NETting the Enemy May Cause Collateral Damage to Self

The Emerging Role of Prostaglandin E2 in Regulating Stem Cell Function

There Goes the Neighborhood: The Leukemic Microenvironment Co-Opts Normal Hematopoietic Progenitor Cells From Their Supportive Marrow Niche

Down-Regulation of PML: A Wake-Up Call for Leukemia-Initiating Cells

Increased Risk of VTE Associated With Impaired Clot Lysis: A New Dimension to Virchow's Triad

Optimism and Caution on the Use of MSCs in Patients Undergoing HSCT for Hematologic Malignancies

Clinical Penetrance of HFE Hereditary Hemochromatosis, Serum Ferritin Levels, and Screening Implications: Can We Iron This Out?

A Bank Without Assets: Ex Vivo Storage Depletes RBC NO Bioactivity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only